26. August 2019
Transglutaminase-Newsletter | August 2019
Paving the way to a new automated FXIII activity assay!
Just recently, Technoclone (Vienna, Austria) and Zedira presented a joint poster at the 27th ISTH Congress in Melbourne, Australia. The scientists involved, Martina Leiter, Ralf Pasternack, Christian Büchold, and Nikolaus Binder concluded:
“The fully automated TECHNOFLUOR FXIII Activity assay run on the new Ceveron s100 haemostasis analyzer is an appropriate method for fast and accurate determination of this critical factor in the stabilization of blood clots. With a high degree of linearity over a wide assay range, this new assay shows excellent recovery of EQA samples, demonstrating high agreement with other FXIII activity assays on the market.”
In this context, please find below our reagents targeting FXIII (F13, plasma transglutaminase) flanked by selected coagulation products:
Selection of Factor XIII products
Drug Discovery at Zedira targeting FXIIIa
Zedira developed direct-acting FXIIIa blockers for safe anticoagulation. This unique and promising approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs. Zedira scientists used structure-assisted drug design to develop potent and selective compounds while deciphering the structure of active coagulation factor XIII.
Structure of Active Coagulation Factor XIII
In the inactive state, recombinant FXIII exists as a dimer. Upon binding of the irreversible acting blocker ZED1301 (A108) and three calcium ions per subunit, FXIII dissociates and the ß-barrel 1 and ß-barrel 2 domains undergo a remarkable shift exposing the active site (upper left). The crystal structure of FXIII in its active conformation provides detailed information on an atomic level regarding the role of calcium in the activation process. Calcium coordination affects the shape of the active site of FXIII and triggers the formation of the catalytic dyad (H342, E401).
New automated FXIII activity assay
Transglutaminase-Newsletter | August 2019Paving the way to a new automated FXIII activity assay!
Just recently, Technoclone (Vienna, Austria) and Zedira presented a joint poster at the 27th ISTH Congress in Melbourne, Australia. The scientists involved, Martina Leiter, Ralf Pasternack, Christian Büchold, and Nikolaus Binder concluded:
“The fully automated TECHNOFLUOR FXIII Activity assay run on the new Ceveron s100 haemostasis analyzer is an appropriate method for fast and accurate determination of this critical factor in the stabilization of blood clots. With a high degree of linearity over a wide assay range, this new assay shows excellent recovery of EQA samples, demonstrating high agreement with other FXIII activity assays on the market.”
In this context, please find below our reagents targeting FXIII (F13, plasma transglutaminase) flanked by selected coagulation products:
Selection of Factor XIII products
Assays
| Art. No. | Name | Unit | Price |
| A101 |
FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH | 10 mg | 520 € |
| F001 |
FXIII-Assay Kit |
1 Kit | 575 € |
Inhibitors
| Art. No. | Name | Unit | Price |
| T101 |
1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride | 10 mg | 480 € |
| A108 |
Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH | 5 mg | 480 € |
Special product
| Art. No. | Name | Unit | Price |
| G101 |
Gly-Pro-Arg-Pro-amide | 25 mg | 370 € |
FXIII
| Art. No. | Name | Unit | Price |
| T027 |
Human blood coagulation Factor XIII-A, recombinant | 200 µg | 370 € |
| T070 |
Human Factor XIIIa, activated | 200 µg | 520 € |
| T050 |
Human blood coagulation Factor XIII B subunit | 200 µg | 370 € |
New!
| Art. No. | Name | Unit | Price |
| T222 | Human alpha Thrombin, recombinant | 100 NIH Units | 185 € |
Antibodies
| Art. No. | Name | Unit | Price |
| A016 |
Polyclonal antibody to human blood coagulation factor XIII (A-subunit) | 500 µg | 365 € |
| A032 |
FITC-labeled polyclonal antibody to human factor XIII (A-subunit) | 200 µg | 395 € |
| A074 |
Polyclonal antibody to human blood coagulation factor XIII (B-subunit) | 200 µg | 365 € |
| A077 |
FITC-labeled polyclonal antibody to human factor XIII (B-subunit) | 200 µg | 395 € |
| A076 |
DD-XLink-mab | 100 µg | 365 € |
Drug Discovery at Zedira targeting FXIIIa
Zedira developed direct-acting FXIIIa blockers for safe anticoagulation. This unique and promising approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs. Zedira scientists used structure-assisted drug design to develop potent and selective compounds while deciphering the structure of active coagulation factor XIII.
Structure of Active Coagulation Factor XIII
In the inactive state, recombinant FXIII exists as a dimer. Upon binding of the irreversible acting blocker ZED1301 (A108) and three calcium ions per subunit, FXIII dissociates and the ß-barrel 1 and ß-barrel 2 domains undergo a remarkable shift exposing the active site (upper left). The crystal structure of FXIII in its active conformation provides detailed information on an atomic level regarding the role of calcium in the activation process. Calcium coordination affects the shape of the active site of FXIII and triggers the formation of the catalytic dyad (H342, E401).
Press release: Zedira announces ISO 9001:2015 certification
Zedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
Artikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
Preview: Catalogue Editorial 2019
Tridegin as FXIIIa inhibitor
Microbial transglutaminase: from discovery to market
Tissue transglutaminase inhibitors
Tissue transglutaminase in Alzheimer’s Disease
Factor XIIIa: novel target for anticoagulation?
Microbial transglutaminase for site-specific protein conjugation
Transglutaminase antibodies in ataxia